Marc B. Garnick, MD

Marc B. Garnick, MD

Harvard University

Boston, Massachusetts

Dr. Garnick is the Gorman Brothers Professor of Medicine at Harvard Medical School and the Beth Israel Deaconess Medical Center, where he also directs the hospital’s role as a tertiary cancer center for 7 affiliated community cancer centers. He has dedicated his career to the development of new therapies for prostate cancer. He serves as the Editor-in-Chief for The Annual Report on Prostate Diseases, formerly Perspectives on Prostate Disease. He served as the initial academic co-principal investigator for the commonly used prostate cancer drug leuprolide (Lupron). In addition to his academic affiliations, Dr. Garnick founded the Hershey Family Foundation for Prostate Cancer Research at Beth Israel Deaconess Medical Center, serves as medical adviser to World Book Encyclopedia, and is an active advisory member of several FDA panels and advisory committees. He has served on the boards of trustees of the Perelman School of Medicine at the University of Pennsylvania and of Penn Medicine. Dr. Garnick is also a Trustee Emeritus of Bowdoin College in Brunswick, Maine.

Talks by Marc B. Garnick, MD

How Well Do You Know Doublets and Triplets? – A Pop Quiz

How Well Do You Know Doublets and Triplets? – A Pop Quiz

Posted by | Sep 2024

Marc B. Garnick, MD, tests knowledge on doublet and triplet therapies in prostate cancer. In this quiz-themed 13-minute presentation, he poses a series of questions. After each, he discusses the correct response.

Dr. Garnick begins by matching prostate cancer stages—such as non-metastatic castration-resistant, metastatic castration-sensitive, first-line castration-resistant, and castration-resistant post-docetaxel—with corresponding clinical trials. He incorporates key studies, including SPARTAN, PROSPER, ARAMIS, TITAN, and PREVAIL, and therapies like apalutamide, enzalutamide, daralutamide, and abiraterone in his questions. He also quizzes his audience on side effects and NCCN Guidelines for treating metastatic disease.

The presentation provides a unique comprehensive examination of the landscape of doublet and triplet therapies in prostate cancer, emphasizing the critical importance of personalized treatment approaches based on a detailed understanding of clinical trial data and drug-specific side effect profiles.

Read More
The Importance of Diagnosing and Treating Oligometastatic Prostate Cancer and ADT Usage

The Importance of Diagnosing and Treating Oligometastatic Prostate Cancer and ADT Usage

Posted by | Jun 2024

Dr. Marc Garnick explores the diagnosis and treatment of oligometastatic prostate cancer with the strategic use of androgen deprivation therapy (ADT). Advanced imaging techniques are essential for identifying oligometastatic disease, such as PET scans and advanced MRI. These technologies enhance the precision of detecting small metastatic lesions, facilitating timely and appropriate treatment decisions. By reducing androgen levels that fuel prostate cancer growth, the strategic use of ADT not only helps in controlling the primary tumor but also in managing metastatic lesions, thereby extending the therapeutic window and improving overall survival rates.
Dr. Garnick also addresses the timing and duration of ADT in the context of oligometastatic prostate cancer. He highlights individualized treatment plans based on patient-specific factors, including the extent of disease, patient health status, and response to initial therapies. This personalized approach ensures that patients receive the most effective treatment while minimizing potential side effects associated with prolonged ADT usage.

Read More
Review of the New Standard in Treatment and Global Issues: Androgen Deprivation Treatment (ADT), Chemotherapy, Androgen Receptors Inhibitors, and Androgen Synthesis Inhibitors

Review of the New Standard in Treatment and Global Issues: Androgen Deprivation Treatment (ADT), Chemotherapy, Androgen Receptors Inhibitors, and Androgen Synthesis Inhibitors

Posted by | May 2023

Marc B. Garnick, MD, Gorman Brothers Professor of Medicine at Harvard Medical School and the Beth Israel Deaconess Medical Center, reviews current literature on the treatment of prostate cancer. Dr. Garnick focuses specifically on Androgen Deprivation Therapy (ADT,) Chemotherapy, Androgen Receptor Inhibitors, and Androgen Synthesis Inhibitors.

In this presentation, Dr. Garnick explores the current landscape of Advanced Prostate Cancer Treatments, the use of triplet therapies in combating metastatic Castration-Sensitive Prostate Cancer (mCSPC), and the possibility of avoiding ADT by combining advanced imaging techniques with Metastases-Directed Therapy (MDT).

Read More

Standard Treatments and Global Perspective

Posted by | Jan 2022

Marc B. Garnick, MD, the Gorman Brothers Professor of Medicine at Harvard Medical School and the Beth Israel Deaconess Medical Center, summarizes recent developments in nomenclature, disease states, and standard treatments for advanced prostate cancer. Using material from a chapter he wrote for ASCO-SEP with David J. Einstein, MD, Assistant Professor of Medicine at Harvard Medical School, Dr. Garnick begins by considering the new language used to describe different states of advanced prostate cancer, including non-metastatic castrate-sensitive prostate cancer (nmCSPC), non-metastatic castrate-resistant prostate cancer (nmCRPC), metastatic castrate-sensitive prostate cancer (mCSPC), and oligometastatic prostate cancer. He then discusses new standards of care for these different states, highlighting recent research indicating the benefits of using darolutamide, enzalutamide, and apalutamide in the nmCRPC setting, and explaining how to appropriately layer and sequence therapies across disease states. He briefly looks at the role of next-generation sequencing in informing the potential benefit of PARP or PD-L1 inhibitors and touches on bone considerations in mCRPC. Dr. Garnick concludes with some comments on the global inequities of prostate cancer treatment, citing data on the significant disparity in mortality-to-incidence rate of prostate cancer in high-income countries compared to low- to middle-income countries.

Read More
  • 1
  • 2

Join the GRU Community

- Why Join? -